The International Cancer of the Pancreas Screening (CAPS) Consortium summit in April 2018 identified potential candidates for screening, as follows: (1) individuals with germline mutations in LKB/STK11 (Peutz–Jeghers syndrome) and CDKN2A (FAMMM) regardless of family history; (2) individuals with germline mutations in BRCA2, PALB2, ATM, and MLH1/MSH2/MSH6 (Lynch syndrome) with at least one affected FDR; and (3) individuals with at least two affected relatives on the same side of the family, of whom at least one is an FDR regardless of gene mutation status. This evidence concerns the gene CDKN2A and cancer.